Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience to $27 from $18 and keeps an Outperform rating on the shares. The firm noted they reported a FY3Q beat and raised its FY23 revenue outlook, with the largest source of upside coming from NGS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TWST:
- Twist Bioscience price target raised to $26 from $20 at Barclays
- Twist Bioscience raises Q4 revenue view to $64M-$63M from $62M-$63M
- Twist Bioscience raises FY23 revenue view to $241M-$242M from $235M-$238M
- Twist Bioscience reports Q3 EPS ($1.01), consensus ($1.14)
- TWST Earnings Report this Week: Is It a Buy, Ahead of Earnings?